11/1/2022 0 Comments Prota lyn review![]() ![]() The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. ![]() It also reviews key players involved in RAF Proto Oncogene Serine/Threonine Protein Kinase (Proto Oncogene c RAF or RAF1 or EC 2.7.11.1) targeted therapeutics development with respective active and dormant or discontinued projects. The latest report RAF Proto Oncogene Serine Threonine Protein Kinase - Pipeline Review, H2 2019, outlays comprehensive information on the RAF Proto Oncogene Serine/Threonine Protein Kinase (Proto Oncogene c RAF or RAF1 or EC 2.7.11.1) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. Report covers products from therapy areas Oncology and Musculoskeletal Disorders which include indications Colorectal Cancer, Melanoma, Non-Small Cell Lung Cancer, Gastric Cancer, Hepatocellular Carcinoma, Liver Cancer, Solid Tumor, Bladder Cancer, Breast Cancer, Esophageal Cancer, Fibrosis, Gastrointestinal Stromal Tumor (GIST), Kidney Cancer (Renal Cell Cancer), Low-Grade Glioma, Lung Cancer, Metastatic Melanoma and Sarcomas. Similarly, the universities portfolio in Preclinical and Discovery stages comprises 3 and 2 molecules, respectively. The molecules developed by companies in Phase II, Phase I, Preclinical and Discovery stages are 3, 4, 5 and 2 respectively. Out of which approximately 14 molecules are developed by companies and remaining by the universities/institutes. RAF Proto Oncogene Serine/Threonine Protein Kinase (Proto Oncogene c RAF or RAF1 or EC 2.7.11.1) pipeline Target constitutes close to 19 molecules. It plays an important role in the control of gene expression involved in the cell division cycle, apoptosis, cell differentiation and cell migration. Once activated the cellular RAF1 protein can phosphorylate to activate the dual specificity protein kinases MEK1 and MEK2 which in turn phosphorylate to activate the serine/threonine specific protein kinases, ERK1 and ERK2. RAF Proto Oncogene Serine/Threonine Protein Kinase (Proto Oncogene c RAF or RAF1 or EC 2.7.11.1) - RAF proto-oncogene serine/threonine-protein kinase or proto-oncogene c-RAF is an enzyme is encoded by the RAF1 gene. ![]() RAF Proto Oncogene Serine Threonine Protein Kinase - Pipeline Review, H2 2019 Prota also provides services in project and construction management, design and construction supervision, systems engineering, quality control and contract management.Speak directly to the analyst to clarify any post sales queries you may have. Prota also has extensive expertise in earthquake engineering and has pioneered innovative methodologies for upgrading buildings and infrastructure to meet the demands of new safety standards. Specialized in architectural and engineering design of high-rise buildings, public facilities including sports complexes, business centers, healthcare and educational facilities, Large scale transportation structures including railway stations and airports, light and heavy industrial buildings as well as execution of feasibility studies, infrastructure projects, and urban and regional planning. Prota is a one of Turkey’s leading engineering consultancy firms with a track record of delivering innovative project design and specialist services around the world.Prota draws from an experienced team of partners and experts from a range of backgrounds including engineers, architects, planners, project managers and BIM specialists. ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |